Post hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011

Basit Öğe Kaydı
dc.authorid0000-0003-2896-4955
dc.authorid0000-0003-4478-7282
dc.contributor.authorLoriot, Y.
dc.contributor.authorCsoszi, T.
dc.contributor.authorMatsubara, N.
dc.contributor.authorShin, S. J.
dc.contributor.authorPark, S. H.
dc.contributor.authorAtduev, V.
dc.contributor.authorGümüş, M.
dc.date.accessioned2025-05-10T19:48:32Z
dc.date.issued2022
dc.departmentİstanbul Medeniyet Üniversitesi
dc.descriptionAnnual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- SEP 09-13, 2022 -- ELECTR NETWORK
dc.description.abstract[No abstract available]
dc.description.sponsorshipEuropean Soc Med Oncol
dc.description.sponsorshipMerck Sharp Dohme LLC
dc.description.sponsorshipMerck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and Eisai Inc., Nutley, NJ, USA.
dc.identifier.doi10.1016/j.annonc.2022.07.1830
dc.identifier.endpageS1339
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.issue7
dc.identifier.scopusqualityQ1
dc.identifier.startpageS1339
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2022.07.1830
dc.identifier.urihttps://hdl.handle.net/20.500.14730/11742
dc.identifier.volume33
dc.identifier.wosWOS:000866211602302
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250302
dc.titlePost hoc analysis of pembrolizumab efficacy in potentially platinum ineligible patients with urothelial carcinoma enrolled in KEYNOTE-052 and LEAP-011
dc.typeConference Object

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
11742.pdf
Boyut:
104.27 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu